Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
Go back to Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry| ACCURIDE CORP (NYSE: ACW) | Delayed: 2.58 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.58 | 52 Week High | $2.84 | |||
| Open | $0.00 | 52 Week Low | $0.74 | |||
| Day High | $2.58 | P/E | N/A | |||
| Day Low | $2.58 | EPS | $-3.93 | |||
| Volume | 1,500 | |||||
